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(BTK)1,	 2.	 This	 kinase	 is	 now	 the	 target	 of	 drugs	 effective	 in	 treating	 numerous	 B	 cell	




B	 cells	must	 rearrange	 first	heavy	and	 then	 light	 chain	 immunoglobulin	 (Ig)	 genes	as	 they	
proceed	 through	 an	 orderly	 programme	 of	 development,	 and	 pass	 corresponding	 quality	
control	 checkpoints	 that	 signal	 the	 expression	 of	 first	 the	 pre-BCR	 and	 then	 the	 BCR	
respectively.	 Confirming	 the	 importance	 for	 developing	 human	 B	 cells	 of	 survival	 signals	
emanating	from	the	pre-BCR/BCR,	autosomal	recessive	causes	of	B	cell	deficiency	have	been	
identified	within	 the	 antigen	 receptor	 itself	 (IGHM,	 IGLL1),	 its	 signalling	 adaptors	 (CD79A,	
CD79B)	and	other	downstream	signal	transducers	(BLNK,	PIK3R1).	Together	with	BTK,	these	
defects	 of	 pre-BCR	 and	 BCR	 signalling	 account	 for	 the	 vast	 majority	 of	 early	 onset	
agammaglobulinemias,	and	 few	patients	 remain	without	a	molecular	diagnosis	 in	 the	USA	
and	Europe4-6.		
	
The	divalent	 cations,	 Ca2+	 and	Mg2+,	 are	well	 established	 as	mediators	 of	 lymphocyte	 cell	
signalling	 and	 inherited	 deficiency	 in	 their	 transmembrane	 transporters	 (ORAI17	 and	
MAGT18)	 causes	 a	 combined	 B	 and	 T	 cell	 immunodeficiency	 and	 a	 T	 or	 NK	 cell	
immunodeficiency	 respectively.	 A	 third	 divalent	 cation,	 Zn2+,	 contributes	 to	 the	 structural	
and	functional	integrity	of	over	3,000	proteins,	and	is	tightly	regulated	by	buffering	and	by	
14	SLC39A	(ZIP)	and	10	SLC30A	(ZnT)	Zn2+	transporters,	which	control	the	movement	of	Zn2+	
between	 the	 cytosol	 and	 the	 extracellular	 space	 or	 cytoplasmic	 organelles9.	 Dietary	 zinc	
deficiency	 causes	 lymphopenia10	 and	 loss	 of	 ZIP10	 has	 also	 been	 associated	 with	 B	 cell	
immunodeficiency	 in	 mice11;	 however,	 the	 mechanism(s)	 by	 which	 Zn2+	 might	 regulate	
lymphocyte	 development	 in	 humans	 are	 not	 established.	 	 The	 MHC	 region	 of	 human	




Here	 we	 report	 a	 novel	 human	 immunodeficiency	 syndrome	 caused	 by	 multiple	 loss	 of	







We	 used	 whole	 exome	 sequencing	 to	 investigate	 patients	 with	 early	 onset	
agammaglobulinemia	 and	 absent	 B	 cells	 of	 unknown	 cause,	 and	 sought	 candidate	
autosomal	 recessive	 disease	 genes	 bearing	 rare	 biallelic	 variants.	 	 Six	 individuals	 from	 5	
kindreds	 of	 white	 European,	 South	 Asian	 or	 Hispanic	 ancestry,	 were	 found	 to	 harbor	
compound	heterozygous	(4	families)	or	homozygous	(1	family)	rare	variants	in	SLC39A7	(Fig.	
1a).	This	gene,	not	previously	linked	to	the	immune	system	other	than	by	its	location	within	
the	 MHC	 complex	 on	 chromosome	 6,	 encodes	 ZIP7,	 a	 ubiquitously	 expressed	 channel	
protein	that	regulates	Zn2+	egress	from	the	endoplasmic	reticulum	(ER)	into	the	cytoplasm12.	
Consistent	 with	 a	 causal	 link	 to	 a	 rare	 autosomal	 recessive	 disease,	 population	 data13	
revealed	 that	 none	 of	 the	 patients’	 variants	 of	 SLC39A7,	 nor	 any	 predicted	 null	
(nonsense/frameshift/essential	 splice-site)	alleles,	occurs	with	a	 frequency	of	greater	 than	
1/1,000	(Supplementary	Fig.	1)	and	none	has	previously	been	found	in	a	homozygous	state.	
In	general,	patients’	 ethnicity	matched	 that	of	 the	population	 in	which	 the	 corresponding	




Affected	 individuals	 presented	 with	 early	 onset	 infections,	 agammaglobulinemia	 and	
absence	of	circulating	B	cells	but	normal	T	cell	numbers	and	proliferative	responses	(Table	1	
and	 Supplementary	 Table	 1).	 Naïve	 T	 cells	 were	 abundant,	 in	 keeping	 with	 age,	 while	
effector	and	memory	subsets	were	correspondingly	reduced	but	not	absent.	The	two	most	





although	 P4	 has	 suboptimal	 growth,	 enteropathy	 and	 liver	 dysfunction	 while	 P5	 has	
seborrheic	dermatitis.	Family	members	who	were	heterozygous	for	a	wild	type	(WT)	and	a	
mutant	allele	demonstrated	normal	immune	function.	Bone	marrow	(BM)	examination	in	P1	
and	 P2	 showed	 a	 progressive	 failure	 of	 B	 cell	 development	with	 an	 excess	 of	 pro-B	 cells	
relative	to	pre-B	cells,	and	an	even	 lower	proportion	of	 immature	B	cells	 relative	to	pre-B	
cells,	similar	to	that	seen	in	XLA	caused	by	mutations	in	BTK	(Fig.	1c)4.		
	
To	 explore	 the	 impact	 of	 disease-associated	 mutations,	 we	 first	 examined	 ZIP7	 protein	





amino	 acid	 substitutions	 were	 illuminated	 by	 modelling	 into	 the	 predicted	 multi-pass	
membrane	 channel	 structure	 of	 human	 ZIP7,	 based	 on	 alignment	 with	 a	 recently	 solved	
bacterial	ZIP	(BpZIP;	26%	sequence	identity)(Fig.	2f,	g	and	Supplementary	Fig	1c)15.	In	most	
cases,	 the	 amino	 acid	 change	 (P190A,	 L217P,	G458A)	 involves	 either	 a	 glycine	 or	 proline,	
residues	that	are	often	conserved	and	known	to	be	critical	for	membrane	protein	structure.	
In	the	case	of	P190A	and	L217P,	the	removal	and	introduction	of	a	proline,	respectively,	is	
likely	 to	affect	 the	conformation	and/or	dynamics	of	 their	 respective	helices,	and	perhaps	










These	analyses	 strongly	 implied	 that	disease	alleles	were	either	null	or	hypomorphic	with	
respect	 to	 Zn2+	 transport	 function.	 To	 test	 this	 hypothesis,	 we	 compared	 the	 function	 of	
P190A	and	E363K	missense	mutants,	which	were	co-expressed	in	the	most	severely	affected	
family	1,	with	WT	ZIP7,	by	injecting	mRNA	transcripts	into	Xenopus	oocytes	and	visualizing	
Zn2+	 ingress	 by	 means	 of	 a	 Zn2+-sensitive	 dye	 (Fig.	 2h	 and	 Supplementary	 Fig.	 2b,	 c).	 In	
keeping	with	hypomorphic	behavior,	 the	Zn2+	 signal	generated	by	either	mutant	ZIP7	was	
significantly	 reduced	 compared	 with	 WT	 (Fig.	 2h),	 despite	 similar	 amounts	 of	 protein	
expression	 (Supplementary	 Fig.	 2c).	 Similar	 data	 were	 obtained	 in	 mammalian	 cells	
transfected	 with	 a	 eCALWY-4	 Fluorescence	 Energy	 Transfer	 (FRET)	 probe	 for	 cytoplasmic	
Zn2+	alongside	WT	or	mutant	ZIP7	 (Supplementary	Fig.	2d	and	e)16.	Taken	 together,	 these	





(B6)	 mice	 carrying	 a	 ZIP7	 P198A	 mutation,	 orthologous	 to	 the	 most	 N	 terminal	 human	
P190A	mutation	found	in	2	independent	kindreds.	We	chose	a	knock-in	rather	than	a	knock-
out	approach	because	we	suspected	complete	loss	of	function	would	be	embryonic	lethal.	
The	 error-prone	 non-homologous	 end-joining	 repair	 pathway	 nonetheless	 generated	 a	
series	of	different	ZIP7	alleles	in	mouse	zygotes,	which	allowed	us	to	investigate	a	range	of	




Mice	 with	 homozygous	 (ZIP7P198A/P198A	 or	 ZIP7H199QV/H199QV)	 or	 compound	 heterozygous	
(ZIP7P198A/H199QV)	hypomorphic	mutations	demonstrated	profound	B	 cell	 immunodeficiency	
(Fig.	 3b),	 whereas	 heterozygous	 mice	 with	 wild-type	 alleles	 had	 normal	 B	 cell	 numbers.	
Other	 effects	 of	 the	 ZIP7	 mutations	 on	 growth	 and	 skin	 varied	 by	 allele,	 with	 severity	
ranging	 from	WT	<	H199QV	<	 P198A	<	 null.	Homozygous	 ZIP7H199QV/H199QV	 and	 compound	
heterozygous	 ZIP7P198A/H199QV	 mice	 showed	 mild	 weight	 restriction	 compared	 with	 WT,	
whereas	ZIP7P198A/P198A	mice	were	growth	retarded	with	mottled	gray	fur,	and	few	of	these	
animals	 survived	 beyond	 6	 weeks	 (Fig.	 3c	 and	 d).	 ZIP7-/-,	 ZIP7-/P198A	 and	 ZIP7-/H199QV	mice	
		 9	
carrying	the	null	allele	could	not	be	obtained.	These	findings	are	consistent	with	an	absolute	
requirement	 for	 some	 residual	 ZIP7	 function	 during	 embryonic	 development,	 albeit	 less	
than	 that	 required	 for	 developing	 B	 cells.	 	 The	murine	 ZIP7	mutations	 therefore	 lead	 to	






IgM-IgD-	 late	pre-B	cells	 (Hardy	fraction	(Fr)	D),	B220+CD43-IgM+IgD-	 immature	B	cells	 (FrE)	
and	recirculating	B220+CD43-IgM+IgD+	mature	B	cells	(FrF)	in	the	ZIP7-deficient	BM	(Fig.	4a	
and	b)18.	Peripheral	B	cell	numbers	were	further	reduced	in	the	spleen	with	progressive	loss	
from	 CD93+IgMhiCD23-	 transitional	 T1	 to	 CD93+IgMhiCD23+	 T2,	 CD93+IgM+CD23+	 T3,	 CD93-
IgM+IgD+CD23+CD21+	follicular	and	CD93-IgMhiIgD-CD23-CD21hi	marginal	zone	B	cells	(Fig.	4a	




FrD	and	FrE	 (Fig	4c).	There	was	no	 rescue	of	B	cell	development	 in	BM	chimeric	mice	 fed	





B	cells	constituted	only	0.76%	(0.76-0.77%,	95%	CI)	of	 total	blood	 lymphocytes	 in	4-week-
old	 ZIP7P198A/P198A	mice,	 compared	 to	 27.96%	 (27.71-28.21%,	 95%	 CI)	 in	 age-matched	WT	
controls;	 and	 serum	 IgM	antibody	concentrations	 in	4-6	week	ZIP7P198A/P198A	and	WT	mice	
were	 104	 µg/ml	 (103-106	 µg/ml,	 95%	 CI)	 and	 383	 µg/ml	 	 (378-388	 µg/ml,	 95%	 CI)	





development	 and	 peripheral	 T	 cell	 numbers	 were	 normal,	 as	 were	 other	 leukocyte	










(Fig.	 4d).	 This	 developmental	 block	 was	 mirrored	 in	 the	 spleen	 with	 progressive	 loss	 of	










mice	 for	RNA-seq,	 and	were	able	 to	obtain	 good	quality	RNA	 from	B220+CD43+CD24+BP1-	
pro-B	(FrB),	 late	pre-B	(FrD)	and	 immature	B	cells	 (FrE)	 (Fig.	5a	and	Supplementary	Figs.	4	
and	 5).	 	 Focusing	 on	 transcripts	 that	 are	modulated	 during	mouse	 B	 cell	 development	 in	
ImmGen	 (www.immGen.org),	 we	 observed	 a	 systematically	 altered	 pattern	 of	 gene	
transcription	consistent	with	developmental	delay	 in	ZIP7-deficient	pre-B	and	 immature	B	
cells,	 but	 not	 at	 the	 earlier	 pro-B	 stage.	 	 Thus,	 the	 few	 ZIP7-deficient	 cells	 bearing	 the	
surface	markers	of	FrE	had	in	fact	failed	to	exit	fully	from	the	transcriptional	profile	of	FrD	
and,	 likewise,	 ZIP7-deficient	 cells	 in	 FrD	 abundantly	 expressed	 transcripts	 normally	
associated	with	 FrC	 (Fig.	 5a	 and	 Supplementary	 Fig.	 5).	 	 In	 contrast,	 few	 transcripts	were	
differentially	 expressed	 between	 WT	 and	 ZIP7-deficient	 FrB	 and	 these	 did	 not	 follow	 a	
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pattern	 of	 developmentally	 coordinated	 gene	 expression	 (Supplementary	 Fig.	 4).	 The	
analysis	 showed	 no	 statistically	 significant	 difference	 in	 expression	 of	 other	 ZIP	 and	 ZnT	
transporters	in	Fr	D	and	E	(see	materials	and	methods).	
	
ZIP7-deficient	 immature	 B	 cells	 continued	 to	 express	 Rag	 and	 Il7r	 genes,	 and	 failed	 to	
upregulate	characteristic	FrE	transcripts	such	as	Tnfrsf13c	 (BAFFR)	and	Ms4a1	 (CD20)	 (Fig.	
5a).		This	indicates	a	failure	of	the	normal	transition	from	late	pre-B	to	immature	B	cells,	at	
which	 stage	 constitutive	 BCR	 signalling	 would	 normally	 repress	 FOXO1-dependent	 genes	
involved	 in	 light	 chain	 gene	 rearrangement	 (Rag1/2	 and	 Irf4)	 and	 cell	 proliferation	 (Il7r),	
followed	 by	 upregulation	 of	 proteins	 including	 BAFFR	 that	 mediate	 peripheral	 survival	
signals19,	 20.	 These	 key	 findings	 were	 confirmed	 at	 the	 protein	 level	 by	 flow	 cytometry,	
including	 the	 failure	 to	 downregulate	 IL7Ra	 (CD127;	 Fig.	 5b)	 and	 upregulate	 BAFFR	 and	
CD20	(Fig.	5c).	The	same	developmental	blockade	was	observed	in	BM	samples	from	both	
patients	that	were	compound	heterozygous	for	the	P190A	and	E363K	variants	(Fig.	5d).	Thus,	










equivalent	 to	 Fractions	 B-C-C’	 in	 B	 cell	 development21,	 22.	 The	 withdrawal	 of	 IL-7	 and	
addition	of	BAFF	to	these	cultures	increased	the	survival	of	IgM+IgD-	immature	and	IgM+IgD+	
mature	B	cells	 from	WT	but	not	from	mutant	cells	 (Fig	6a).	 In	this	way,	the	model	system	
recapitulated	the	developmental	block	seen	in	vivo.		
	
To	measure	 the	 cytoplasmic	 and	 ER	 concentrations	 of	 Zn2+	 at	 the	 point	 of	 blockade,	 we	






concentration	 of	 measured	 fluorophore,	 and	 hence	 free	 Zn2+	 concentrations	 can	 be	





state	 in	 both	 WT	 and	 mutant	 B	 cells	 (Fig.	 6b).	 	 However,	 local	 variations	 in	 Zn2+	
concentration	 would	 most	 likely	 be	 beyond	 the	 temporal	 and	 spatial	 resolutions	 of	 the	












the	 ZIP7P198A/P198A	 mice,	 we	 considered	 the	 possibility	 that	 zinc	 loading	 of	 the	 ER	 could	
nonetheless	drive	an	unfolded	protein	response	(UPR),	as	recently	described	in	the	gut	and	
skin	 of	 gene-targeted	mice	with	 tissue-specific	 ZIP7	 knockout25,	26.	 However,	 our	 RNA-seq	
data	 revealed	 no	 evidence	 of	 an	 UPR	 transcriptional	 signature	 in	 the	 mutant	 pre-B	 or	






(BCL2)	 could	 rescue	 B	 cell	 development	 at	 the	 pre-B	 to	 immature	 stage	 in	 ZIP7P198A/P198A	
mice.	 Introduction	 of	 a	 B	 cell	 specific	Bcl2	 transgene	 (from	 C57BL/6-Tg(BCL2)22Wehi/J)27	
increased	peripheral	B	cell	numbers	in	both	WT	and	ZIP7P198A/P198A	mice	but	did	not	relieve	
the	developmental	block	(Supplementary	Fig.	6b-e).	This	suggested	that	ZIP7	deficiency	was	
not	 simply	 accelerating	 the	 death	 of	 otherwise	 normally	 developing	 B	 cells,	 but	 was	





Ig	 light	 chain	 expression	 for	 the	 pre-B	 to	 immature	 B	 cell	 transition29,	we	 considered	 the	
possibility	 that	 ZIP7	 deficiency	 impaired	 (pre-)BCR	 expression	 or	 signalling.	 To	 bypass	 the	
need	 for	 DNA	 recombination	 by	 RAG1/2	 at	 both	 pro-B	 and	 pre-B	 cell	 stages,	we	 crossed	
ZIP7P198A/P198A	mice	with	animals	expressing	a	 transgenic	anti-hen	egg	 lysozyme	(anti-HEL)-
specific	 BCR	 (SWHEL	mice)30.	 This	 generated	WT	 and	 ZIP7P198A/P198A	immature	 SWHEL	 B	 cells	
expressing	 equivalent	 levels	 of	 surface	 BCR	 (Fig.	 7a-c),	 enabling	 us	 to	 interrogate	 the	
integrity	of	 the	downstream	signalling	pathway.	 	Despite	normal	BCR	expression	 (Fig.	7c),	
ZIP7P198A/P198A	B	 cells	 still	 failed	 to	mature	normally,	as	 indicated	by	 lower	cell	numbers	 in	
the	spleen	(Fig.	7b)	and	an	inability	to	upregulate	CD20	and	BAFFR	(Fig.	7c).	Moreover,	when	
exposed	to	soluble	HEL	(sHEL)	antigen	or	to	anti-IgM,	immature	ZIP7P198A/P198A	SWHEL	B	cells	






variation	 in	 kinase	or	phosphatase	activity.	 Since	Zn2+	 is	widely	 reported	 to	be	a	negative	
regulator	 of	 phosphatases31,32,	 the	 diminished	 cytoplasmic	 Zn2+	 associated	 with	 ZIP7	
deficiency	 could	 be	 expected	 to	 cause	 pathologically	 elevated	 phosphatase	 activity,	 and	
thus	contribute	to	impaired	pre-BCR-	and	BCR-dependent	signalling	at	the	positive	selection	
check-points.	 Constitutive	 phosphatase	 activity	 was	 indeed	 higher	 in	 ZIP7P198A/P198A	
		 14	
compared	to	WT	pre-B	and	 immature	B	cells,	as	measured	by	flow	cytometry	using	a	cell-
permeable	 alkaline	 phosphatase	 substrate	 (Fig.	 8a	 and	 b).	 The	 phosphatase	 and	 tensin	
homolog	(PTEN)	is	among	the	phosphatases	previously	described	as	being	inhibited	by	Zn2+,	
lies	 upstream	of	 FOXO1-dependent	 signalling33,	 and	 contributes	 to	 the	basal	 phosphatase	
activity	measured	 in	 developing	 B	 cells	 (Supplementary	 Fig.	 8a).	 Progressive	 inhibition	 of	






expression	 of	 PLCg2,	 which	 we	 were	 able	 to	 detect	 reliably	 by	 flow	 cytometry	
(Supplementary	Fig.	8b).	However,	crossing	ZIP7P198A/P198A	mice	to	mice	with	B	cell	specific	






Our	 studies	 identify	 a	 novel	 form	of	 autosomal	 recessive	 agammaglobulinemia	 caused	by	
hypomorphic	 mutations	 in	 the	 ER-to-cytoplasmic	 zinc	 transporter	 ZIP7.	 This	 discovery	
implicates	 Zn2+	 as	 the	 third	 divalent	 cation	 associated	 with	 a	 human	 immunodeficiency.	
Despite	 zinc’s	 status	as	 a	 key	player	 in	protein	 structure	and	 function,	we	are	at	 an	early	
stage	in	understanding	its	broader	roles	in	homeostasis	and	human	disease.	Its	tight	control	
by	buffering,	and	the	diversity	of	Zn2+	transporters,	indicate	that	dynamic	regulation	of	Zn2+	
distribution	 is	 critical.	 This	 conclusion	 is	 supported	 by	 knowledge	 that	 mutations	 in	 the	
human	plasma	membrane	Zn2+	transporter,	SLC39A4	(ZIP4),	cause	total	body	Zn	deficiency	
and	 a	 separate	 but	 related	 disease,	 acrodermatitis	 enteropathica34.	 As	 well	 as	 a	





ZIP7	 function.	 It	 was	 recently	 reported	 that	 complete	 loss	 of	 ZIP7	 in	 cell	 lines	 causes	 a	
reduction	 in	 cytoplasmic	 Zn2+	 and	 an	 increase	 in	 ER	 Zn2+	 concentrations	 as	 quantified	 by	
mass	 spectrometry36;	 and	 our	 findings	 show	 that	 germline	 null	mutations	 are	 embryonic	
lethal	in	the	mouse.	Tissue-specific	ZIP7	knock-out	in	the	gut	of	mice	by	cre-mediated	gene	
deletion	 reduces	 intestinal	 epithelial	 cell	 self-renewal	 and	 is	 associated	with	 an	 ER	 stress	





Our	 findings	 emphasise	 the	 specific	 sensitivity	 of	 mammalian	 B	 cell	 development	 to	
perturbations	of	Zn2+	homeostasis.	 	Whereas	most	 tissues	 tolerate	partial	 ZIP7	deficiency,	
developing	B	cells	are	profoundly	affected	and	fail	to	progress	beyond	the	pre-B-cell	stage.	
Such	 developmental	 blockade	 is	 characteristic	 of	 over	 90%	 of	 primary	
agammaglobulinemias,	which	are	 typically	associated	with	 specific	 impairment	of	pre-BCR	
and/or	BCR	signalling4.	Our	data	suggest	that	ZIP7	hypofunction	likewise	impedes	signalling	
by	the	nascent	BCR	during	positive	selection,	and	that	this	may	be	in	part	due	to	defective	
Zn2+-dependent	 inhibition	 of	 phosphatase	 activity.	 In	 the	 chicken	 B	 cell	 line	 DT40,	 which	
does	 not	 possess	 a	 homologue	 of	 ZIP7,	 ZIP9-dependent	 Zn2+	 transport	 was	 similarly	
reported	 to	enhance	BCR	 signalling	by	negatively	 regulating	phosphatase	activity39.	 CD74-
cre	mediated	deletion	of	 ZIP10,	which	 transports	 Zn2+	 across	 the	plasma	membrane,	 also	
reduced	 mature	 B	 cell	 numbers	 and	 BCR-induced	 B	 cell	 proliferation	 in	 mice;	 yet,	
paradoxically,	 this	 was	 reportedly	 associated	 with	 increased	 BCR	 signalling	 and	 reduced	
CD45	activity11.		Unravelling	these	complex	effects	of	individual	transporters	will	require	the	
development	 of	 improved	 reporters	 to	 resolve	 changes	 in	 Zn2+	 levels	 dynamically	 and	 at	
higher	spatial	resolution.		
	







41.	Progression	 through	 these	developmental	 stages	 requires	 the	 sequential	 integration	of	
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(a)	 Pedigrees	 of	 five	 unrelated	 kindreds	 in	which	 subjects	with	 agammaglobulinemia	 and	
absent	 B	 cells	 (P1-P6)	 carry	 the	 indicated	 SLC39A7	 (ZIP7)	 alleles.	 (b)	 Representative	 low	
(scale	bar	40	µm)	and	high-power	(scale	bar	10	µm)	images	of	skin	biopsy	from	patient	P1	
stained	with	hematoxylin	and	eosin,	highlighting	blister	formation	at	the	dermo-epidermal	
junction	 (n=2).	 (c)	 Schematic	 representation	 of	 the	 B	 cell	 precursor	 compartments	within	
the	BM	of	9	age-matched	healthy	donors	(HD),	patients	P1	and	P2	(mutated	ZIP7),	and	12	
disease	controls	with	X-linked	agammaglobulinemia	(XLA),	assessed	by	flow	cytometry.	Pro-











recombinant	 FLAG-tagged	WT	 (WT)	 or	 indicated	missense	 ZIP7	proteins	 in	HEK293T	 cells,	
transfected	 individually	 and	 probed	 with	 primary	 antibodies	 against	 FLAG	 (green)	 and	
calnexin	(red;	orange	signal	thus	indicates	colocalization	in	the	ER).	Scale	bar,	10µm.	(e)	As	
in	 d,	 but	 recombinant	 truncation	 mutants	 were	 not	 FLAG-tagged	 so	 were	 probed	 with	
primary	anti-ZIP7	antibody.		Images	(c-e)	are	representative	of	3	independent	experiments	
and	Pearson	coefficients	were	uniformly	>0.6.	(f	and	g)	The	location	of	missense	mutations	
within	 the	 predicted	 protein	 structure	 of	 ZIP7,	 modelled	 on	 the	 structure	 of	 Bordetella	
pertussis	ZIP	using	PyMOL;	(f)	en	face	and	(g)	side	view	of	ZIP7.	M1	and	M2	represent	Zn2+	
ions	 bound	 within	 the	 channel,	 TM	 indicates	 transmembrane	 region.	 (h)	 Hypomorphic	
human	 SLC39A7	 alleles	 were	 expressed	 in	 Xenopus	 oocytes	 and	 ZIP7-mediated	 Zn2+	 flux	
revealed	following	exposure	of	Zinquin-loaded	oocytes	to	extracellular	zinc	(see	Methods).	
Normalized	mean	fluorescence	signal	 intensity	 is	shown	with	SD	for	one	experiment,	 (WT,	
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n=3	 oocytes;	 P190A,	 n=4;	 E363K,	 n=3,	 uninjected,	 n=2),	 representative	 of	 4	 independent	




of	SLC39A7	 (ZIP7)	 in	mouse	 zygotes	 using	CRISPR/Cas9	 to	 insert	 the	P198A	mutation	 and	
coincidentally	 generate	 an	 allelic	 series	 by	 homologous	 recombination	 (HR)	 and	 non-
homologous	 end	 joining	 (NHEJ),	 here	 showing	 the	 WT,	 Zip7P198A	 (P198A),	 Zip7H199QV	
(H199QV)	 and	 Zip-	 (null)	 alleles.	 (b)	 Total	 B220+	 cell	 population	 as	 percentage	 of	
lymphocytes	 in	 the	BM	of	 25-day-old	mice,	where	 circles	 represent	 individual	mice	 (n=27	
WT,	 6	 H199QV	 Hom;	 13	 P198A/H199QV	 and	 18	 P198A	 Hom);	 data	 are	 pooled	 from	 6	
independent	experiments;	bars	are	mean	and	95%	confidence	intervals	(CI)	and	comparison	
is	by	one-way	ANOVA	(F=51.71;	DF=63)	*=	p<0.0001.	 (c-d)	The	appearance	(c)	and	weight	
(d)	 of	 3-4-week-old	mice	 of	 different	 genotypes,	where	 circles	 in	 (d)	 represent	 individual	
mice	 (n=74	WT,	 14	H199QV	Hom;	 30	 P198A/H199QV	 and	 31	 P198A	Hom);	weights	were	
collected	 over	 time;	 bars	 are	 mean	 and	 95%	 CI,	 and	 comparison	 is	 by	 one-way	 ANOVA	
(F=50.23;	DF=148)*=p<0.0001.	(e)	Phenotypes	associated	with	combinations	of	ZIP7	alleles.	
	
Figure	 4.	 ZIP7	 deficiency	 leads	 to	 a	 B	 cell-intrinsic	 failure	 in	 development.	 (a)	
Representative	flow	cytometry	of	B	cell	development	in	BM	and	spleen	of	WT	and	P198A-
Hom	mice,	gating	on	Hardy	Fractions	(Fr)	A-F	in	the	BM	and	total	B220+CD19+	B	cells	in	the	




B	 cells.	 	 n=	 6	 mice	 per	 genotype,	 bars	 show	 means	 and	 95%	 CI,	 representative	 of	 5	
independent	experiments.		(c)	Absolute	numbers	of	B	cell	subsets	in	the	BM	(upper	panel)	
and	 spleen	 (lower	 panel)	 from	 lethally	 irradiated	 CD45.1	mice	 reconstituted	 for	 8	 weeks	
with	 CD45.2	WT	 or	 P198A-Hom	 BM	 (gated	 as	 in	 a).	 n=	 5	mice	 per	 genotype,	 bars	 show	
means	 and	 95%	 CI,	 are	 representative	 of	 3	 independent	 experiments.	 	 (d)	 The	 relative	
proportion	of	B	cell	 subsets	 in	BM	(above)	and	spleens	 (below)	of	 lethally	 irradiated	mice	






transition.	 (a)	 Heatmap	 showing	 relative	 abundance	 of	 selected	 differentially	 expressed	
transcripts	 in	 sorted	 B	 cells	 from	 Fr	 D	 and	 E	 in	 WT	 and	 P198A-Hom	 mice,	 where	 rows	
represent	individual	mice.	(b)	Median	CD127	expression	on	WT	and	P198A-Hom	B	cells	from	
FrE,	 with	 representative	 histogram	 (left);	 graph	 (right)	 shows	 median	 expression	 in	
individual	mice	(n=5	per	genotype),	bars	are	means	and	95%	CI;	comparison	by	unpaired	t	
test,	 *=p<0.0001	 (representative	 of	 3	 independent	 experiments).	 (c-d)	 BAFFR	 and	 CD20	
staining	in	murine	B	cells	from	FrD	(c)	and	human	pre-B	cells	(d)	comparing	P198A-Hom	and	




Hom	 IL-7	dependent	B	 cell	 lines,	 showing	 representative	 flow	cytometry	before	and	after	
stimulation	with	BAFF.	(b)	FLIM	fluorescent	decays	images	of	Zn2+	in	IL-7-dependent	WT	and	
P198A-Hom	B	cells	 transduced	with	 the	cytoplasmic	eCALWY-4	and	eCALWY-6	and	ER	ER-
eCALWY-4	 and	 ER-eCALWY-6	 Zn2+	 reporters.	 Samples	 are	 representative	 of	 cells	with	 the	
mean	 Zn2+	 concentrations	 in	 (c),	 and	 scale	 bar	 5	 µm.	 Relative	 Zn2+	 concentration	
proportional	 to	 a	 color	 scale	 showing	 theoretical	 reporter	 occupancy.	 (c)	 Relative	 Zn2+	
concentration	 in	cytoplasm	and	ER	of	 IL-7	dependent	WT	and	P198A-Hom	cells	expressing	
eCALWY-4	and	eCALWY-6	reporters.	Dots	represent	the	FLIM	fluorescent	decay	in	individual	
B	 cells,	 with	 data	 pooled	 from	 three	 independent	 experiments	 (*=p<0.0001);	 bars	 are	
means	 with	 95%	 CI	 and	 comparison	 by	 t	 Test.	 	 (d-e)	 Super-resolution	 micrographs	 of	
activated	 primary	 human	 B	 cells	 or	 HEK293T	 cells,	 stained	 for	 endogenous	 ZIP7	 (yellow),	
calnexin	 (red)	 and	 surface	 membrane	 (green).	 	 (d)	 Paired	 raw	 and	 deconvolved,	 3D-
rendered	images	are	shown	for	B	cells	(left,	scale	bar	1	µm)	and	HEK293T	cells	(right,	scale	
bar	 5	 µm).	 	 (e)	 Detailed	 view	 of	 indicated	 area	 in	 (d).	 	 (f)	 Violin	 plot	 depicting	minimum	
distance	from	the	centre	of	each	ZIP7+ve	“particle”	to	the	plasma	membrane	of	individual	B	
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gated	 on	 B220+CD24+CD21-HEL+IgD-	 cells;	 n=3	 mice	 per	 genotype;	 representative	 of	 6	
independent	 experiments.	 (d)	 Mean	 phospho-specific	 antibody	 binding	 to	 indicated	
intracellular	signalling	molecules	downstream	of	the	BCR,	5	min	after	stimulation	of	whole	
BM	from	WT/	SWHEL	(closed	circles)	and	P198A-Hom/	SWHEL	(open	circles)	mice	with	media	
alone	 or	 10µg/ml	 anti-IgM	 (two	 experiments)	 or	 1,000ng/ml	 soluble	 Hen	 Egg	 Lysozyme	
(sHEL)	and	gated	for	Fr	E	as	in	a.	In	this	figure,	circles	represent	values	from	individual	mice	





showing	phosphatase	activity	 in	 the	pre-	 (IgM-)	 to	 immature	 (IgM+)	B	cell	 transition;	plots	
representative	of	3	separate	experiments,	with	n=4	mice	per	genotype	in	each	experiment.	
(b)	Mean	phosphatase	activity	in	B	cell	Hardy	Fractions	A-F	and	myeloid	cells	(B220-CD43+),	
from	 WT	 (closed	 circles)	 and	 P198A-Hom	 (open	 circles)	 BM.	 Results	 are	 pooled	 from	 3	
independent	 experiments,	 for	 a	 total	 of	 11	mice	per	 group,	with	 comparison	by	 two-way	
ANOVA	 (F	 5.158;	DF	 6);	 *p=0.0438;	 **p=0.0010;	 ***p<0.0001.	 (c)	Mean	 phospho-specific	
antibody	binding	to	indicated	intracellular	signalling	molecules	downstream	of	the	BCR,	30	
min	after	treatment	of	WT	(closed	circles)	and	P198A-Hom	(open	circles)	BM	cells	with	the	
PTEN	 specific	 inhibitor	 BpV(phen),	 in	 the	 absence	 of	 BCR	 stimulation;	 gated	 on	
B220+CD24+CD21-HEL+IgD-	SWHEL	 transgenic	 B	 cells.	 In	 this	 figure,	 circles	 represent	 values	
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Patient	 P1	 P2	 P3	 P4	 P5	 P6	
ZIP7	variant	1	 P190A	 P190A	 L217P	 E451X	 T395I	 P190A	
ZIP7	variant	2	 E363K	 E363K	 Q372X	 G458A	 T395I	 L217P	
age	(months)		
at	presentation	 <1	 <1	 12	 23	 <1	 26	
IgG	(g/L)	 1.0	 *30.1	 0.14	 *4.58	 <1.4	 <1.7	
IgA	(g/L)	 0.25	 0.16	 <0.06	 <0.06	 **0.17	 <0.07	
IgM	(g/L)	 <0.22	 **0.19	 <0.04	 <0.04	 **0.23	 0.09	
















Children	 with	 humoral	 immunodeficiency	 and	 absent	 B	 cells	 and	 their	 relatives	 were	
recruited	under	research	protocols	approved	by	 local	ethical	review	(Newcastle	and	North	
Tyneside	 1	 Research	 Ethics	 Committee;	 Institutional	 Review	 Board	 of	 St.	 Jude	 Children's	
Research	 Hospital).	 Peripheral	 blood	 was	 evaluated	 in	 accredited	 clinical	 laboratories	 by	
standard	 methods,	 including	 flow	 cytometric	 immunophenotyping.	 Primary	 dermal	
fibroblast	 cultures	 were	 established	 from	 punch	 skin	 biopsies,	 as	 part	 of	 the	 routine	
diagnostic	workup	of	P1	and	P2,	who	also	underwent	bone	marrow	examination.	 Further	
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The	 generation	 and	 phenotyping	 of	 the	 ZIP7	 mutant	 mice	 models	 was	 carried	 out	 in	
accordance	with	Animal	[Scientific	Procedures]	Act	1986,	with	procedures	reviewed	by	the	
clinical	 medicine	 animal	 care	 and	 ethical	 review	 body	 (AWERB),	 and	 conducted	 under	
project	licenses	PPL30/2966	and	PPL	P79A4C5BA.	Animals	were	housed	in	specific	pathogen	
free	conditions,	with	 the	only	 reported	positives	on	health	screening	over	 the	entire	 time	
course	 of	 these	 studies	 being	 for	Helicobacter	 hepaticus	 and	 Entamoeba	 spp.	 All	 animals	
were	housed	in	social	groups,	provided	with	food	and	water	ad-libitum	and	maintained	on	a	





A	 CRISPR/Cas9	 nuclease	 was	 designed	 against	 exon	 2	 of	 Slc39a7	 (5’-
GTTACTTACCCAAGGCATGC-3’)	 using	 the	 MIT	 CRISPR	 design	 tool	 (crispr.mit.edu),	 which	
encompassed	 the	murine	 equivalent	 (Proline-198)	 of	 the	 human	Proline-190	 residue.	 The	
target	 site	 protospacer	 was	 cloned	 as	 a	 linker,	 which	 was	 formed	 by	 annealing	 two	
oligonucleotides	 (5’-CACCGTTACTTACCCAAGGCATGC-3‘,	 5‘-
AAACGCATGCCTTGGGTAAGTAAC-3‘)	 into	 a	 sgRNA	 scaffold	 within	 the	 pX330-U6-
Chimeric_BB-CBh-hSpCas9	 plasmid	 (Addgene	 #42230)	 via	 the	 BbsI	 restriction	 site,	
generating	 plasmid	 pX330-ZIP7.	 A	 single	 stranded	 oligonucleotide	 (ssODN)	 (5’-
CACCGCTCTCTGCTCCAGATCCTGCTCAGTTTTGCTTCCGGGGGGCTCCTGGGTGATGCGTTCCTCCA
CCTCATCGCGCATGCATTGGGTAAGTAACTTGTGGGCTCCGCCTCAAAGGCTTAAGCGGTTTTGTTC-
3’)	 harboring	 the	 murine	 equivalent	 of	 the	 desired	 P190A	 (chr6_33169678_C_G)	 point	
mutation,	 together	 with	 a	 silent	 mutation	 used	 to	 mark	 the	 mutated	 allele	 with	 an	NsiI	
restriction	 site,	 was	 used	 as	 a	 template	 for	 homology-directed	 repair.	 The	 activity	 of	 the	




For	 the	 generation	 of	 the	 P198A	 knock-in	 mouse	 model,	 C57BL/6J	 (B6)	 zygotes	 were	
microinjected	with	20	ng/μl	of	sgRNA,	10	ng/μl	NLS-Cas9	mRNA	and	20	ng	of	ssODN.	sgRNA	
was	 synthesized	by	 in	 vitro	 transcription	using	 the	MEGAshortscript™	T7	Transcription	Kit	
(ThermoFisher	 Scientific)	 from	 a	 DNA	 template	 to	 add	 a	 5’	 T7	 polymerase	 binding	 site,	
prepared	by	PCR	amplification	of	the	pX330-ZIP7	plasmid.	Capped	mRNA	for	NLS-Cas9	was	
generated	 by	 cloning	 the	NLS-Cas9	 cDNA	 from	 pX330-ZIP7	 into	 pcDNA3.1,	 linearizing	 the	
plasmid	 with	 XhoI	 and	 using	 this	 as	 a	 template	 for	 in	 vitro	 transcription	 using	 the	
mMESSAGE	mMACHINE®	 T7	 Ultra	 Kit	 (ThermoFisher	 Scientific).	 In	 vitro	 transcribed	 RNAs	
were	 purified	 using	 the	 MEGAclear	 Kit	 (ThermoFisher	 Scientific)	 and	 diluted	 prior	 to	
microinjection	in	10	mM	Tris.HCl	pH7.5,	0.1	mM	EDTA	pH	8.0.	Microinjected	zygotes	were	
cultured	overnight	to	the	two-cell	stage	and	surgically	implanted	into	pseudopregnant	CD1	
females.	 Founder	 mice	 harboring	 the	 P198A	 allele	 in	 combination	 with	 putative	 loss-of-
function	 alleles,	 were	 identified	 by	 genotyping	 using	 a	 PCR	 (5’-
GTTCTTAATCGGTGGGAAGCTCC-3’	 and	 5’-CAGCACACCAGTCCCTGGTTTT-3’)	 amplifying	 a	
region	 of	 Slc39a7	 exon	 2,	 followed	 by	 NsiI	 digestion	 to	 detect	 the	 incorporation	 of	 the	
template	 sequence.	 All	 founder	mice	were	 bred	with	WT	 C57BL6/J	mice	 and	 the	 correct	
P198A	allele,	along	with	a	number	of	putative	loss-of-function	indel	alleles,	were	segregated	
in	the	resulting	F1	offspring.	Mice	carrying	the	P198A,	H199QV	and	null	alleles	were	crossed	
to	 pure	 B6	 for	 at	 least	 6	 generations	 (to	 minimize	 the	 risk	 of	 co-segregating	 mutations	
caused	 by	 off	 target	 mutagenesis)	 and	 intercrossed	 to	 generate	 homozygotes	 and	
compound	heterozygotes	of	the	viable	alleles.		
	
BCL2	 (C57BL/6-Tg(BCL2)22Wehi/J),	 swHEL	 (C57BL/6-IghVh10-Brink/J),	 Mb1Cre	
(Cd79b<tm1(cre)Reth),	mice	were	maintained	on	 the	B6	background,	PTEN	 floxed	 (PTENf)	

















the	 indicated	 doses	 of	 anti-IgM	 F(ab)2	 (Jackson	 Immunoresearch),	 sHEL	 (Sigma)	 for	 5	








minutes	 on	 ice	 and	 counterstaining	with	HyHEL9	 (a	 gift	 from	 Jason	Cyster)	 conjugated	 to	




otherwise	 specified:	 B220	 (RA3-6B2)	 AlexaFluor700,	 BV605,	 PE-Cy7,	 PerCP-Cy5.5;	 mouse	
BAFFR	 (7H22-E16)	 PE	 from	 BD;	 BP-1	 PE	 from	 BD;	 CD3	 (17-A2)	 BV421;	 CD4	 (GK1.5)	
		 31	
AlexaFluor700;	 CD8	 (53-6.7)	 Per-CP-Cy5.5;	 CD8	 (53-6.7)	 PerCP-Cy5.5	 and	 PE;	 	 CD11b	
(M1/70)	 APC;	 CD11c	 (N418)	 FITC;	 CD19	 (6D5)	 AlexaFluor700;	 CD20	 (SA275A11)	 APC;	
CD21/35	(7E9)	APC-Cy7;	CD21/35	(7E9)	BV605	from	BD;	CD23	(EBVCS-5)	PE	from	BD;	CD23	
(B3B4)	PE-Cy7;	CD24	(M1/69)	FITC,	AlexaFluor700,	BV605;	CD25	(PC61)	PE	and	BV421;	CD43	
(S7)	 APC	 and	 PerCP-Cy5.5	 from	 BD;	 CD44	 (IM7)	 FITC;	 CD45.1	 (A20)	 PE-Cy7	 and	 APC-Cy7;	
CD45.2	(104)	APC,	BV421	and	BV605;	CD62L	(MEL14)	APC;	CD127	(A7R34)	PE-Cy7	and	APC;	
F4/80	(BM8)	PE-Cy7;	Ly6c	(HK1.4)	PerCP-Cy5.5;	Ly6g	(1A8)	AlexaFluor700;	NK1.1	(PK136)	PE-




mAbs	 against	 the	 following	 human	 antigens	 (clone)	 were	 purchased	 from	 BD	 Bioscience	





CD138	 (B-A38)	 PE	 from	Diaclone);	 cyCD79a	 (HM47)	 PE	 from	Beckman	 Coulter;	 CyCD179a	
(VpreB)	(4G7)	PE	from	Beckman	Coulter;	CD33	(P67.6)	PerCP-Cy5.5;	CD16	3G8)	PerCP-Cy5.5;	
















kits	 (Agilent	 Technologies).	 Paired-end	 sequencing	 was	 carried	 out	 on	 a	 HiSeq	 2500	
sequencing	 system	 (Illumina)	 generating	 100-base	 reads.	 Sequences	 were	 aligned	 to	 the	
GRCh37	 reference	 build	 of	 the	 human	 genome,	 using	 the	 BWA	 aligner43.	 Downstream	
processing	 and	 variant	 calling	 were	 performed	 with	 the	 GenomeAnalysis	 Toolkit44,	
SAMtools45,	 and	 Picard.	 	 Substitution	 and	 InDel	 calls	 were	 made	 with	 the	 GATK	 Unified	
Genotyper.	 All	 variants	 were	 annotated	 with	 an	 annotation	 software	 system	 that	 was	





P198A/P198A	mutants,	8	weeks	after	 reconstitution,	and	sorted	using	a	FacsARIA	 III	 (BD),	
using	 the	 following	gating	strategy:	viable,	B220+CD43+CD45.1-CD45.2+CD24+BP1-	 (FrB/pro-




from	 NIST-certified	 DNA	 plasmids),	 2.5	mM	 dNTPs	 (Thermo-Fisher),	 2.5	 µM	Oligo	 (Oligo-
dT30VN.)	and	immediately	frozen	in	dry	ice.	
	





manufacturer	 (Illumina)),	 according	 to	 manufacturer’s	 instructions.	 Following	 library	
preparation,	 the	samples	were	sequenced	on	an	 Illumina	HiSeq	4000	 instrument	as	75	bp	
paired-end	reads.		Bioinformatic	analysis	was	performed	using	in-house	pipelines	and	tools	
(https://github.com/CGATOxford/CGATPipelines)	 and	 47.	Briefly,	 reads	were	aligned	 to	 the	
mm10	mouse	genome	using	hisat2	version	2.1.048,	and	reads	were	quantified	over	feature	
annotations	 (ensemble81)	 using	 featureCounts	 program	 version	 1.4.6	within	 the	 Subread	
software	package49.	 	DESeq2	was	used	for	statistical	analysis	of	the	differential	expression	
for	 each	 gene	 between	WT	 and	 ZIP7P198A/P198A	mice.	 A	 gene	was	 considered	 differentially	
expressed	if	the	log2	fold	change	was	+/-	1	and	significance	value	was	Padj	<	0.05,	which	was	





SLC39A7	 cDNA	was	amplified	 from	 total	RNA	extracted	 from	EBV-transformed	B	cells	 and	
cloned	in	pCMV6-AC-myc-DDK	plasmid	between	AscI	and	NotI	(Origene).	Mutagenesis	was	
performed	using	the	Quick	Change	Mutagenesis	kit	(Agilent	Technologies).	Expression	of	WT	
and	 mutant	 isoforms	 was	 assessed	 by	 immunoblotting	 total	 protein	 extracted	(RIPA)	 48	
hours	post-transfection	 (FuGENE®	 HD	 Transfection	 Reagent,	 Promega)	 with	500ng	of	
plasmid	 into	 mycoplasma-free	 HEK293T	 cells.		 Anti-ZIP7	 (HPA053999,	 Sigma	 Aldrich)	
and	anti-Flag	 (F1804,	 Sigma	Aldrich)	antibodies	were	 used	 for	 ZIP7	 detection.	Anti-GAPDH	
(5174,	 Cell	 Signaling)	was	 used	 for	 normalization.	 Alternatively,	 ZIP7	 was	 transfected	
into	HEK293T	cells	 on	 8-well	 chamber	 slide	 (Merck	Millipore	 PEZGS0816)	 pre-coated	with	
Cell-tak	 (Fisher	 Scientific	 10317081).	 Cells	 were	 later	 fixed	 with	4%	 formaldehyde	 in	 PBS	
(28906,	 ThermoFisher	 Scientific),	 permeabilized	 with	0.1%	 Triton-X	 in	 PBS,	 stained	 with	
primary	 anti-ZIP7	 (HPA053999,	 Sigma	 Aldrich)/anti-Flag	 (F7425,	 Sigma	 Aldrich),	 anti-
Calnexin	 (610524B,	 Dbiosciences)	 and	 secondary	goat	 anti-rabbit	 IgG	 Alexa	 Fluor	 594	 (A-




Primary	 B	 cells	 were	 isolated	 from	 whole	 blood	 donated	 by	 healthy	 individuals	 using	
RosetteSep™	 Human	 B	 Cell	 Enrichment	 Cocktail.	 Purity	 of	 B	 cells	 was	 assessed	 by	 flow	
cytometry,	 and	 found	>80%	 CD19	 staining,	 <1%	 CD3	 staining,	 <4%	 CD14	 staining.	 B	 cells	
were	activated	by	50ng/ml	IL-4	(204-IL,	R&D	Systems),	0.5μg/ml	CD40	ligand	(6420-CL,	R&D	
Systems)	 and	10	μg/ml	 IgM	 (16-5099-85,	 Invitrogen)	 for	 at	 least	 48	hours	 before	 seeding	
onto	8-well	chamber	slides	pre-coated	with	Cell-tak.	Cells	were	fixed	with	4%	formaldehyde	




confocal	microscope	with	white	 light	 super	 continuum	 lasers	 and	3	 STED	depletion	 lasers	
(592	nm,	660	nm	and	775	nm)	using	STED	WHITE	HC	PL	APO	CS2	100x/1.40	OIL	lens.	 	The	
DAPI	and	AF488	channels	were	acquired	 in	 confocal	mode	while	 the	AF594	and	ATTO647	
channels	were	acquired	in	confocal	and	STED	mode.		
	
Deconvolution,	 colocalization	 analysis	 and	 object	 analysis	 were	 performed	 with	 Huygens	
18.04	from	SVI	(www.svi.nl).	Proximity	measurements	were	performed	using	the	Advanced	











well	 of	 a	 6	well	 plate	 in	 a	 final	 volume	of	 4	ml/well.	Half	 the	enriched	RPMI	 volume	was	







On	day	 7	 of	 culture,	 IL-7-dependent	BM	 cells	were	 transduced	with	 Zn2+	 FRET	biosensors	
eCALWY-4	 and/or	 eCALWY-6	 engineered	 with	 Cerulean	 (donor)	 and	 Citrine	 (acceptor)51	
targeted	either	to	the	cytosol	or	the	ER.	ER-eCALWY-4	and	ER-eCALWY-6	are	targeted	to	the	
ER	 by	 an	 N-terminal	 preproinsulin	 sequence	 and	 C-terminal	 Lys-Asp-Glu-Leu	 (KDEL)	
sequence.		For	the	purposes	of	these	experiments,	the	eCALWY	constructs	were	cloned	into	
retroviral	pMX-DEST-puro-derived	vectors.	Filtered	retroviral	supernatants,	harvested	48	hr	
following	 co-transfection	 of	 BOSC23	 cells	 with	 7	 μg	 pCL-Eco	 and	 7	 μg	 pMX-DEST-puro-
derived	 plasmids,	were	 used	 to	 infect	 the	 cell	 cultures	 in	 the	 presence	 of	 polybrene	 (2.5	
µg/ml)	and	HEPES	(20	mM)	by	spinoculation	(850	x	g	for	90	min	at	30°C).	After	a	rest	period	
































with	 UK	 Home	 Office	 guidelines.	 Oocytes	 were	 prepared	 and	 maintained	 as	 described	
elsewhere54.	SLC39A7	 plasmids	 (see	above)	were	 further	engineered	by	addition	of	 a	RFP	





Zn	 transport	 assay:	Oocytes	were	 incubated	 in	20	µM	Zinquin	 (Enzo	 Life	 Sciences)	 for	30	






pigmented	vesicles,	which	 lie	 just	beneath	the	plasma	membrane.	 	After	deconvolution	of	
the	 images	 the	 zinquin	 signal	 was	 visible	 as	 discontinuous	 punctate	 staining	 within	 the	
intervening,	 superficial	 cytoplasm.	 	 To	 quantitate	 this,	 representative	 fields	 of	 50x50	 µM	
were	 specified	 and	 3	 adjacent	 focal	 planes	 (1.2	 µM	 interval)	 were	 analysed	 together	 in	
ImageJ.		To	subtract	background	staining,	ImageJ	was	used	to	specify	the	shape	(size	of	0.2-
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cDNA	 from	 cells	 sorted	 using	 the	 aforementioned	 gating	 strategy	 was	 used	 in	 an	 XBP-1	
splicing	RT-PCR	assay56.	PCR	products	were	run	on	a	2.5%	agarose	gel.	Negative	and	positive	




GraphPad	 Prism	 Software	 was	 used	 for	 statistical	 analyses,	 and	 unpaired,	 two	 tailed	





RNA-sequencing	 data	 generated	 for	 this	 study	 (fig	 5,	 supplementary	 figs	 4,5)	 have	 been	
deposited	in	the	Gene	Expression	Omnibus	(GEO)	under	accession	code	GSE108178.		Other	
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Supplementary Figure 1 
Allele frequency, and predicted severity and evolutionary conservation of mutated residues in SLC39A7. 
(a): Population frequency of putative pathogenic alleles of SLC39A7 (ZIP7) from the GNOMAD database13. (b) Combined Annotation 
Dependent Depletion (CADD)14 scores vs maximum mean allele frequencies of the SLC39A7 variants recorded in this study (red circles) 
and/or GNOMAD Database (blue circles for predicted null mutations (frameshift/stop/essential splicing), green circle (Inframe INDELS 
mutations) or grey circle (missense mutations)). None of the predicted null mutations or Inframe INDELS mutations were found in the 
homozygous state. (c) Alignments of human ZIP7, mouse ZIP7 and Bordetella pertussis ZIP, generated as two pairwise alignments with 
human ZIP7 in BLAST-P, highlighting residues mutated in patients with agammaglobulinemia (missense, yellow; nonsense, pink) and 




Supplementary Figure 2 
Mutant forms of ZIP7 are expressed but display reduced Zn transporter activity. 
(a) Fluorescence micrographs revealing expression of endogenous ZIP7 in primary dermal fibroblasts from healthy control or P1, stained 
with antibody against ZIP7 (red) and DAPI (blue).  Scale bar, 20µm. (b) Impaired Zn2+ conductance of mutant forms of ZIP7 expressed 
in Xenopus oocytes, visualized by zinquin fluorescence.  Left, fluorescence micrographs showing Zn2+-related zinquin signal and right, 
pairwise image analysis in ImageJ, as described in Methods.  Images are representative of 4 independent experiments as exemplified in 
Fig 2h. (c) Western blot of detergent extracts of Xenopus oocytes injected in parallel with those visualized in (b), revealing expression of 
the recombinant ZIP7 proteins. Images are representative of 3 independent experiments. (d-e) Cytoplasmic Zn2+ concentration in HEK-
293T cells stably expressing the genetically encoded cytoplasmic Zn2+ sensor eCALWY-4 and transfected with empty vector (EV), or 
vectors encoding WT, E363K (d) or P190A (e) ZIP7 proteins. Cytoplasmic Zn2+ concentration was calculated by comparing the steady 
state live cell fluorescence intensity with maximum and minimum signals obtained in the presence of TPEN and zinc pyrithione 
respectively, as described in Methods. Total number of cells analyzed was 80 (EV), 55 (WT), 26 (E363K) and 42 (P190A) across 2-4 
experiments. Columns show means and bars the standard error. Comparisons were by one-way ANOVA with Bonferroni’s correction; * 




Supplementary Figure 3 
Normal T cell development in P198A homozygous mice. 
(a-b) Representative flow cytometry of T cell subsets in the thymus (a) and spleen (b) of WT and P198A-Hom mice. Representative of 3 
independent experiments (c-d) The percentage of B220+ B cells, naïve (CD62L+CD44-), activated (CD62L-CD44+) and memory 
(CD62L+CD44+) CD4+ and CD8+ T cells, NK cells (NK1.1+CD3-), neutrophils (B220-CD3-Ly6g+CD11b+Ly6c+) and monocytes (B220-CD3-
Ly6c++F4/80-) within the leukocyte populations in wild-type (closed circles) and P198A-Hom (open circles) blood (c) and spleen (d). 
Representative of three separate experiments; circles represent individual mice, 5 WT and 5 P198A-Hom; bars means and 95% CI, and 
comparisons by two way ANOVA with Bonferroni’s correction for multiple comparison; *p<0.0001. (e) The relative proportion of thymic or 
splenic CD4+ and CD8+ cells, in lethally irradiated mice reconstituted for 8 weeks with 70:30 mixtures of wild type (WT) or ZIP7P198A/P198A 





Supplementary Figure 4 
Transcriptomic analysis of WT and ZIP7 deficient B cells from Hardy Fraction B 
B220+CD43+CD24+BP1- pro-B cells were sorted flow-cytometrically and whole transcriptome analysis performed by RNAseq on 100 cell-
samples from WT and P198A-Hom mutant mice. We identified genes whose transcription varied by at least two-fold between WT and 
P198A-Hom mice with Padj < 0.05 (see Methods). (a-c) Heatmaps show the relative expression level of the subset of these genes that 
are also differentially expressed during normal B cell development: (a) during the transition from Fractions A to B (reduced, purple and 
raised, blue), (b) during the transition from Fractions B to C (reduced, red and raised, green) and (c) between Fractions B and D (reduced, 
yellow and raised, orange), based on the ImmGen database (www.immGen.org). In each heatmap, the far left column indicates the 






Supplementary Figure 5 
Transcriptomic analysis of WT and P198A-Hom B cells from Hardy Fractions D and E. 
B220+CD43-IgM-IgD- late pre-B (FrD) and B220+CD43-IgM+IgD- immature B cells (FrE) were flow-sorted and whole transcriptome analysis 
performed by RNA-seq on 100 cell-samples from WT and P198A-Hom mice.  We identified genes whose transcription varied by at least 
two-fold between WT and P198A-Hom mice with Padj < 0.05 (see Methods) and filtered these against sets of genes that are also 
differentially expressed at the indicated stages of normal B cell development (www.immGen.org). (a-b) Heatmaps showing the relative 
expression of the subset of genes that show differential expression between wild-type and P198A-Hom B cells in Hardy Fraction D and 
also (a) between Fractions C and D (reduced, yellow and raised, red) and (b) between Fractions D and E (reduced, green and raised, 
blue) of normal mice. (c) Heatmaps showing the relative expression level of the subset of genes that show differential expression between 
wild-type and P198A-Hom B cells in Hardy Fraction E and also between Fractions D and E (reduced, green and raised, blue) of normal 
mice. In each heatmap, the far left column indicates the direction of change expected from ImmGen; each of the remaining columns 




Supplementary Figure 6 
The B cell developmental arrest caused by ZIP7 deficiency is not associated with ER stress and is not corrected by expression 
of the pro-survival factor BCL2. 
(a) RT-PCR assay for the ER-stress-associated shortened Xbp1-splice variant (Xbp1s). Results show RT-PCR of cDNA from WT (lanes 
1-3) or P198A-Hom (lanes 4-6) flow-sorted B cells from FrD and FrE. The controls were tunicamycin treated (Tm) or untreated (Un) 
mouse embryonic fibroblasts (MEFs). Three mice were studied per genotype in the single experiment shown. (b-c) Representative flow 
cytometry analysis of B cell development and maturation in BM (b) and spleen (c) of WT and P198A-Hom mice, with and without co-
expression of a Bcl2 transgene (upper and lower panels).  Gates corresponding to Fr A-F in the BM and total (B220+CD19+), follicular 
(Fo, CD23+CD21+) and Marginal Zone (MZ, CD23-CD21hi) B cells in the spleen are highlighted. (d-e) Absolute numbers of B cells, gated 
as in (b-c), in Hardy Fractions in the BM (d) and in splenic subsets (e) from WT, P198A-Hom, WT BCL2 transgenic (BCL2) and P198A-
Hom BCL2 transgenic (P198A-Hom BCL2) mice, here n=3 per group and representative of 4 independent experiments. Bars show means 




Supplementary Figure 7 
Normal TCR signaling and threshold for activation ZIP7-deficient thymocytes. 
(a-c) Mean phospho-specific antibody binding to indicated intracellular signaling molecules downstream of the TCR, 5 min after 
stimulation of WT (closed circles) and P198A-Hom (open circles) thymocytes with anti-CD3, gated on CD4+CD8+ (a), CD4+ (b) and CD8+ 
cells (c). (d-f) Mean phospho-specific antibody binding to indicated intracellular signaling molecules 30 min after treatment of WT (closed 
circles) and P198A-Hom (open circles) thymocytes with the PTEN specific inhibitor BpV(phen), in the absence of TCR stimulation, gated 
CD4+CD8+ (d), CD4+ (e) and CD8+ cells (f). In this figure, circles represent values from individual mice (n=3 mice per genotype), bars are 




Supplementary Figure 8 
PTEN contributes to phosphatase activity, but PTEN haploinsufficiency does not rescue B cell development in ZIP7 deficiency; 
normal PLCg2 kinase expression in P198A-Hom cells 
(a) Reduced phosphatase activity in B cells from PTEN-deficient PTENffMb1Cre (n=2) mice compared with wild-type Mb1Cre controls (n=4). 
Plots show gating on the pre-B (Fraction D) population in these animals (left panel) and reduced phosphatase activity thereof in the 
absence of PTEN (middle panel, red fill: PTENffMb1Cre; blue fill: PTENwtMb1Cre); quantification in right panel. Bars show means and 95% 
CI; n=4 PTENwtMb1Cre and 2 PTENf/fMb1Cre mice; experiment done once. (b) Mean anti-PLCg2 antibody staining in wild-type/P198A-
heterozygote (closed circles) and P198A-Hom (open circles) SWHEL immature (B220+CD43-HEL+IgM+IgD-) B cells and B220-CD43- 
controls; bars show means and 95% CI (n=3 mice per group, experiment done once). (c-d) B cell numbers in irradiated CD45.1+ B6 mice 
reconstituted with WT (open triangles), PTENf/+Mb1Cre heterozygote (open circles), P198A-Hom (filled triangles) or P198A-Hom 
PTENf/+Mb1Cre compound mutant BM (filled circles), gated on Hardy Fractions A-F in the BM (c) and total B220+CD19+, follicular 
B220+CD19+CD23+CD21+ and marginal B220+CD19+CD23-CD21++ B cells in the spleen (d). Each symbol represents an individual mouse 




Supplementary Table 1 
	
Feature\Patient P1 P2 P3 P4 P5 P6 











age at presentation (m) <1 < 1 12 23 < 1 26 
age at lymphocyte 
subset analysis (yr) 0.1 0 14 8 3 6 
age at FU (yr) 5.5 3.5 32 16 11 18 
height (cm) [centile] 101.1 [3rd] 85 [3rd] 160 [40th] 152 [5th] 140 [25th] 173 [90th] 
weight (kg) [centile] 16.3 [10th] 13.4 [10th] 60 [50th] 38 [<0.4th] 27 [50th] 71 [73rd] 
bacterial infections yes yes yes yes yes yes 























parental origin N European N European N European S Asian Hispanic N European 
treatment HSCT HSCT IVIG IVIG IVIG SCIG 
IgG (g/L) 1 30.1§ 0.14 4.58§ <1.4 <1.7 
IgA (g/L) 0.25 0.16* <0.06 <0.06 0.17* <0.07 
IgM (g/L) < 0.22 0.19* <0.04 <0.04 0.23* 0.09 
CD3+ (/ul) 9036 1308 NA 1121 94.5% 6180 
CD4+ T cell (/ul) 8031 1031 NA 566 61.1% 4141 
CD8+ T cell (/ul) 893 268 NA 468 25.4% 2044 
naïve (% of CD4+) 14 48 NA 81 80 NA 
naïve (% of CD8+) 51 183 NA 52 71 NA 
CD4:CD8 ratio 8.99 3.85 NA 1.21 2.4 2 
TCRab(% of CD3+) 98 NA NA 82 93 NA 
HLA-DR+ of CD3+ 34 1 NA NA NA NA 
proliferation to PHA normal normal NA normal NA NA 
NK cell (/ul) 2097 78 NA 215 4.7% 163 
B cell (%) <0.01 <0.01 <0.01 <0.02 <0.01 <0.01 	 *Declining to undetectable; NA, not available; §, on intravenous immunoglobulin (IVIG); HSCT, hematopoietic  
 stem cell transplantation; SCIG, subcutaneous immunoglobulin; FU, follow up; m, month;  PHA, phytohemagglutinin 
